Pneumoconiosis due to asbestos and other mineral fibers
ICD-10 Code: J61 · Body Part: Head/Brain (TBI)
QME Evaluation Process
Pulmonary function testing (spirometry, DLCO, lung volumes), chest imaging (CT preferred), exposure history documentation. Chapter 5 respiratory impairment per AMA Guides 5th Edition.
Typical Impairment Rating
10-50% WPI based on PFT results and functional limitation
AMA Guides Edition
5th Edition
Common Treatments
Related Conditions
Body Part Guide
Head/Brain (TBI) Evaluation Guide
Impairment rating methods, common conditions, and QME evaluation protocols
QME Specialties for Pneumoconiosis due to asbestos and other mineral fibers
Find a QME Specialist
Browse QME-certified physicians who evaluate pneumoconiosis due to asbestos and other mineral fibers and related head/brain (tbi) conditions in California.
Browse Neurology Physicians →Frequently Asked Questions
What is Pneumoconiosis due to asbestos and other mineral fibers (J61)?
Pneumoconiosis due to asbestos and other mineral fibers is an ICD-10 diagnosis code (J61) classified under Respiratory conditions. It affects the Head/Brain (TBI) and is commonly encountered in California workers' compensation claims. QME physicians evaluate this condition using AMA Guides 5th Edition protocols.
How is J61 rated for impairment?
The typical whole person impairment (WPI) range for Pneumoconiosis due to asbestos and other mineral fibers is 10-50% WPI based on PFT results and functional limitation. The exact rating depends on clinical findings, imaging, and the evaluation method (DRE or ROM) chosen by the QME physician per AMA Guides 5th Edition.
What is the QME evaluation process for J61?
Pulmonary function testing (spirometry, DLCO, lung volumes), chest imaging (CT preferred), exposure history documentation. Chapter 5 respiratory impairment per AMA Guides 5th Edition.
What treatments are common for Pneumoconiosis due to asbestos and other mineral fibers?
Common treatments for Pneumoconiosis due to asbestos and other mineral fibers include Exposure cessation, Pulmonary rehabilitation, Supplemental oxygen for severe cases, Monitoring for malignancy. Treatment appropriateness and outcomes are considered during the QME evaluation when determining permanent and stationary status and apportionment.